Agena Bioscience Enters into Partnership with nRichDX
Friday, April 14, 2023
Agena Bioscience and nRichDX have advanced their existing technical collaboration to a commercial partnership that co-promotes their products to researchers developing liquid biopsy applications on the Agena MassARRAY platform.
Agena collaborates with nRichDX to provide clinical investigators with research solutions which delivers greater assay sensitivity and improved detection of rare analytes on the MassARRAY platform.
The Revolution Sample Prep System routinely extracts higher yields of even the rarest of variant transcripts from bodily fluids as compared to other methods, which in turn increases the detection sensitivity of the MassARRAY platform. Together, these systems are a welcomed advancement towards the detection of rare cancer genetic targets in liquid biopsy samples, which have applications in the area of cancer detection, therapy selection, treatment monitoring and minimal residual disease.
The early detection of rare oncology analytes is the primary goal of liquid biopsy research and development; however, existing methods of analyte extraction are not often able to extract sufficient rare analytes, like circulating cell-free tumour DNA (ctDNA), to enable the development of highly sensitive liquid biopsy-based assays.
